
Novartis will be highlighting data for its multiple sclerosis drug Gilenya at this year’s American Academy of Neurology (AAN) annual …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

